Abstract:Association between VTE and cancer has been recognised for over a century. The incidence of occult or overt malignancy in patients with thrombosis is 7–26%. VTE has been shown to impart poor prognosis in patients with cancer and cancer also adversely impacts on the survival of patients with VTE. It is desirable to identify patients with thrombosis at increased risk of malignancy or those with minimal risk, thus avoiding unnecessary investigations. We propose here a predictive model using age and quantitative D-dimer level at presentation along with site of thrombosis. Materials and Methods This study included 696 (M: 358; F: 338) consecutive patients from the prospectively maintained database of patients with venous thrombosis at a University Teaching Hospital, between February 2001 and December 2005. All patients underwent a Doppler ultrasound examination to confirm the diagnosis and determine the extent of venous thrombosis. At presentation, D-dimer assays were done using Bio-Merieux kit containing mouse monoclonal antibody. The database was regularly updated (6 monthly) using hospital information systems, questionnaires and clinical review Thrombosis recurrence was always confirmed by Doppler ultrasound examination. All Patients with thrombosis received standard treatment with low molecular weight heparin and warfarin. Statistical analysis was carried out using SPSS 13.0 for Windows software. A logistic multivariate regression model was fitted using complete data records from 621 patients with an indicator variable for a subsequent cancer as the response and age, the natural logarithm of the quantitative D-dimer level and the site of the thrombosis as explanantory variables. The fitted model was validated using an additional set of independent data. Results The model correctly identified the VTE patients without malignancy in 473 out of 480 cases (98.5% accuracy). But the model was ineffective in identifying VTE patients with malignancy (13 out of 141; 9% accuracy). The area under the receiver operating characteristic (ROC) curve was 0.72, indicating that the test developed for predicting cancer for the model data was reasonably good. Our model shows that below a predicted probability of 0.10 less than 5% of the patients actually developed cancer (9/190) whereas for a predicted probability of 0.19 less than 10% of patients actually developed cancer (27/276). In the validation dataset of 93 patients with VTE, the model correctly identified the number of patients without malignancy in 72 out of 73 cases (98.6% accuracy). One-sample binomial tests revealed that there was no significant difference in the number VTE patients with cancer between the model and the validation dataset for the predicted probabilities of 0.10 and 0.19 (p-values of 0.650 and 0.246 respectively). Conclusions This suggests that our model is useful for identifying patients at minimal risk of developing cancer with VTE. This predictive model has been validated by an independent dataset demonstrating reproducibility. This model will enable a focused and a cost-effective strategy of screening for a malignancy in patients with VTE.

Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics

Clinical Features of Cancer Patients with Venous Thromboembolism

The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update

Prevalence and treatment of venous thromboembolism in patients with solid tumors

Variation in thromboembolic complications among patients undergoing commonly performed cancer operations

Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis

Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study

Incidence of recurrent venous thromboembolism and bleeding complications in patients with cancer and isolated distal deep vein thrombosis

Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis

Clinical analysis of cancer associated venous thromboembolism in hospitalized patients with malignant solid tumors in real-world practices.

PCN9 Epidemiology of Venous Thromboembolism Among Cancer Patients in Taiwan

Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta‐analysis

Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis

Outcomes and cost of deep venous thrombosis among patients with cancer.

Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease

A Predictive Model to Identify Patients with Venous Thromboembolism (VTE) at Minimal Risk of Malignancy.

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer

Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study